HIGHLIGHTS
- who: Xinyu Wu and colleagues from the Peking University People`s Hospital, China have published the Article: Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers, in the Journal: (JOURNAL)
- what: Up to this date, no molecular marker has been unanimously agreed on as a powerful predictor in neoadjuvant setting.
- how: In this study 2 to 3 cycles of ipilimumab combined with chemotherapy were used before surgery. The overall results indicated that pembrolizumab is well tolerated. The results of this study again suggest that ctDNA clearance rates are . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.